Analysis of association between LRPAP1 seropositivity and clinical characteristics
| Variable . | LRPAP1 positive (N = 41), frequency (%) or median (range) . | LRPAP1 negative (N = 271), frequency (%) or median (range) . | P . |
|---|---|---|---|
| Study | |||
| Elderly | 15 (37) | 95 (35) | .86 |
| Treatment (elderly) | |||
| R-CHOP | 10 (67% of 15) | 54 (57% of 94) | .58 |
| R-FC | 5 (33% of 15) | 40 (43% of 94) | |
| Study | |||
| Younger | 26 (63) | 176 (65) | .86 |
| Treatment (younger) | |||
| R-Benda | 0 (0% of 25) | 1 (1% of 171) | .85 |
| R-CHOP | 9 (36% of 25) | 66 (39% of 171) | |
| R-CHOP/ R-DHAP | 16 (64% of 25) | 104 (61% of 171) | |
| Age, y | 61 (34-74) | 60 (33-85) | .77 |
| Sex | |||
| Male | 29 (71) | 218 (80) | .15 |
| Stage | |||
| 1 | 0 (0) | 1 (0) | .44 |
| 2 | 4 (10) | 15 (6) | |
| 3 | 3 (7) | 36 (13) | |
| 4 | 34 (83) | 219 (81) | |
| BM inv | |||
| 1 | 31 (76) | 194 (72) | .71 |
| ECOG-PS | |||
| 2 to 4 | 0 (0) | 13 (5) | .23 |
| WBC, G/L | 7.250 (1.130-98.700) | 7.660 (1.045-675.000) | .40 |
| LDH/ULN | 0.86 (0.41-3.94) | 0.91 (0.29-6.52) | .31 |
| MIPI score | |||
| 1 | 5.73 (4.81-7.68) | 5.79 (4.07-8.84) | .31 |
| MIPI group | |||
| Low | 18 (44) | 117 (43) | .73 |
| Intermediate | 15 (37) | 86 (32) | |
| High | 8 (20) | 68 (25) | |
| Ki-67, %* | 20 (8-87) | 20 (2-93) | .72 |
| Ki-67, ≥30%* | 6 (21% of 29) | 52 (30% of 174) | .38 |
| Response | |||
| OR | 39 (100% of 39) | 235 (91% of 257) | .092 |
| CR | 9 (23% of 39) | 74 (29% of 257) | .57 |
| MRD EOI | |||
| PB neg | 19 (76% of 25) | 91 (68% of 134) | .49 |
| PB and BM neg | 17 (63% of 27) | 81 (58% of 140) | .67 |
| MRD Y1 | |||
| PB neg | 23 (85% of 27) | 117 (77% of 152) | .45 |
| PB and BM neg | 21 (78% of 27) | 107 (69% of 155) | .49 |
| Time from treatment start to LRPAP1-status, d | 1 (−14 to 1413) | 1 (−133 to 1413) | .37 |
| Variable . | LRPAP1 positive (N = 41), frequency (%) or median (range) . | LRPAP1 negative (N = 271), frequency (%) or median (range) . | P . |
|---|---|---|---|
| Study | |||
| Elderly | 15 (37) | 95 (35) | .86 |
| Treatment (elderly) | |||
| R-CHOP | 10 (67% of 15) | 54 (57% of 94) | .58 |
| R-FC | 5 (33% of 15) | 40 (43% of 94) | |
| Study | |||
| Younger | 26 (63) | 176 (65) | .86 |
| Treatment (younger) | |||
| R-Benda | 0 (0% of 25) | 1 (1% of 171) | .85 |
| R-CHOP | 9 (36% of 25) | 66 (39% of 171) | |
| R-CHOP/ R-DHAP | 16 (64% of 25) | 104 (61% of 171) | |
| Age, y | 61 (34-74) | 60 (33-85) | .77 |
| Sex | |||
| Male | 29 (71) | 218 (80) | .15 |
| Stage | |||
| 1 | 0 (0) | 1 (0) | .44 |
| 2 | 4 (10) | 15 (6) | |
| 3 | 3 (7) | 36 (13) | |
| 4 | 34 (83) | 219 (81) | |
| BM inv | |||
| 1 | 31 (76) | 194 (72) | .71 |
| ECOG-PS | |||
| 2 to 4 | 0 (0) | 13 (5) | .23 |
| WBC, G/L | 7.250 (1.130-98.700) | 7.660 (1.045-675.000) | .40 |
| LDH/ULN | 0.86 (0.41-3.94) | 0.91 (0.29-6.52) | .31 |
| MIPI score | |||
| 1 | 5.73 (4.81-7.68) | 5.79 (4.07-8.84) | .31 |
| MIPI group | |||
| Low | 18 (44) | 117 (43) | .73 |
| Intermediate | 15 (37) | 86 (32) | |
| High | 8 (20) | 68 (25) | |
| Ki-67, %* | 20 (8-87) | 20 (2-93) | .72 |
| Ki-67, ≥30%* | 6 (21% of 29) | 52 (30% of 174) | .38 |
| Response | |||
| OR | 39 (100% of 39) | 235 (91% of 257) | .092 |
| CR | 9 (23% of 39) | 74 (29% of 257) | .57 |
| MRD EOI | |||
| PB neg | 19 (76% of 25) | 91 (68% of 134) | .49 |
| PB and BM neg | 17 (63% of 27) | 81 (58% of 140) | .67 |
| MRD Y1 | |||
| PB neg | 23 (85% of 27) | 117 (77% of 152) | .45 |
| PB and BM neg | 21 (78% of 27) | 107 (69% of 155) | .49 |
| Time from treatment start to LRPAP1-status, d | 1 (−14 to 1413) | 1 (−133 to 1413) | .37 |
EOI, end of induction; inv, involvment; neg, negative; OR, overall response at end of induction (i e, complete, unconfirmed complete, or partial remission); PB, peripheral blood; Y1, 1 y after end of treatment.
For Ki-67 index, 29 positive and 174 positive patients were evaluable.